PCI Biotech Valuation
| PCIB Stock | NOK 1.33 0.07 5.56% |
Today, the entity appears to be overvalued. PCI Biotech Holding holds a recent Real Value of 1.17 per share. The prevailing price of the entity is 1.33. Our model determines the value of PCI Biotech Holding from evaluating the entity fundamentals such as shares owned by insiders of 31.97 %, and Return On Asset of -0.4 as well as inspecting its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that PCI Biotech's price fluctuation is extremely dangerous at this time. Calculation of the real value of PCI Biotech Holding is based on 3 months time horizon. Increasing PCI Biotech's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the PCI stock is determined by what a typical buyer is willing to pay for full or partial control of PCI Biotech Holding. Since PCI Biotech is currently traded on the exchange, buyers and sellers on that exchange determine the market value of PCI Stock. However, PCI Biotech's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.33 | Real 1.17 | Hype 1.33 | Naive 1.37 |
The intrinsic value of PCI Biotech's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence PCI Biotech's stock price.
Estimating the potential upside or downside of PCI Biotech Holding helps investors to forecast how PCI stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of PCI Biotech more accurately as focusing exclusively on PCI Biotech's fundamentals will not take into account other important factors: PCI Biotech Total Value Analysis
PCI Biotech Holding is at this time expected to have takeover price of 25.47 M with market capitalization of 81.93 M, debt of 1.28 M, and cash on hands of 116.12 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the PCI Biotech fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
25.47 M | 81.93 M | 1.28 M | 116.12 M |
PCI Biotech Investor Information
About 32.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.44. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. PCI Biotech Holding recorded a loss per share of 2.35. The entity had not issued any dividends in recent years. The firm had 405:376 split on the 17th of September 2018. PCI Biotech Holding is not in a good financial situation at the moment. It has a very high risk of going through financial straits in April.PCI Biotech Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. PCI Biotech has an asset utilization ratio of 4.61 percent. This suggests that the Company is making 0.0461 for each dollar of assets. An increasing asset utilization means that PCI Biotech Holding is more efficient with each dollar of assets it utilizes for everyday operations.PCI Biotech Ownership Allocation
PCI Biotech owns a total of 37.33 Million outstanding shares. PCI Biotech Holding has substantial amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company maintains, if the real value of the entity is less than the current market value, you may not be able to make money on it.PCI Biotech Profitability Analysis
The company reported the revenue of 6.27 M. Net Loss for the year was (88.39 M) with profit before overhead, payroll, taxes, and interest of 6.27 M.About PCI Biotech Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of PCI Biotech Holding. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of PCI Biotech Holding based exclusively on its fundamental and basic technical indicators. By analyzing PCI Biotech's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of PCI Biotech's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of PCI Biotech. We calculate exposure to PCI Biotech's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of PCI Biotech's related companies.PCI Biotech Holding ASA, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for the treatment of cancer through its photochemical internalization technology platform. PCI Biotech Holding ASA was founded in 2000 and is headquartered in Oslo, Norway. PCI BIOTECH operates under Pharmaceuticals And Biosciences classification in Norway and is traded on Oslo Stock Exchange. It employs 11 people.
8 Steps to conduct PCI Biotech's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates PCI Biotech's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct PCI Biotech's valuation analysis, follow these 8 steps:- Gather financial information: Obtain PCI Biotech's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine PCI Biotech's revenue streams: Identify PCI Biotech's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research PCI Biotech's industry and market trends, including the size of the market, growth rate, and competition.
- Establish PCI Biotech's growth potential: Evaluate PCI Biotech's management, business model, and growth potential.
- Determine PCI Biotech's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate PCI Biotech's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Other Information on Investing in PCI Stock
PCI Biotech financial ratios help investors to determine whether PCI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in PCI with respect to the benefits of owning PCI Biotech security.